Effects of glucagon-like peptide-1 receptor agonists on kidney function and safety in type 2 diabetes patients

被引：4
|
作者：
Kim, Min Kyung [1 ]
Kim, Doo-Man [1 ]
机构：
[1] Hallym Univ, Coll Med, Dept Internal Med, Div Endocrinol,Kangdong Sacred Heart Hosp, Seoul, South Korea
来源：
JOURNAL OF DIABETES INVESTIGATION | 2021年 / 12卷 / 06期
关键词：
D O I：
10.1111/jdi.13552
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Glucagon-like peptide-1 receptor agonists have been recommended in diabetic kidney disease patients.
引用
收藏
页码：914 / 916
页数：3
相关论文
共 50 条
  • [1] Kidney Outcomes With Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes
    Mosenzon, Ofri
    Schechter, Meir
    Leibowitz, Gil
    ADVANCES IN CHRONIC KIDNEY DISEASE, 2021, 28 (04) : 347 - 360
  • [2] Effects of Glucagon-Like Peptide-1 Receptor Agonists on beta-Cell Function in Patients with Type 2 Diabetes
    Grandy, Susan
    Shaunik, Alka
    Hardy, Elise
    JOURNAL OF DIABETES & METABOLISM, 2016, 7 (01)
  • [3] Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists
    Hansen, K. B.
    Knop, F. K.
    Holst, J. J.
    Vilsboll, T.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2009, 63 (08) : 1154 - 1160
  • [4] Glucagon-like peptide-1 receptor agonists for treating chronic kidney disease in patients with type 2 diabetes
    Khan, Irfan
    Lanktree, Matthew B.
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2024, 196 (40) : E1345 - E1345
  • [5] Safety of once-weekly glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes
    Patel, Dhiren
    JOURNAL OF THE AMERICAN ASSOCIATION OF NURSE PRACTITIONERS, 2018, 30 : S29 - S42
  • [6] Safety of Once-weekly Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes
    Frias, Juan Pablo
    JOURNAL OF FAMILY PRACTICE, 2018, 67 (06): : S25 - S34
  • [7] Efficacy and safety of high-dose glucagon-like peptide-1, glucagon-like peptide-1/glucose-dependent insulinotropic peptide, and glucagon-like peptide-1/glucagon receptor agonists in type 2 diabetes
    De Block, Christophe E. M.
    Dirinck, Eveline
    Verhaegen, Ann
    Van Gaal, Luc F.
    DIABETES OBESITY & METABOLISM, 2022, 24 (05): : 788 - 805
  • [8] COPD Exacerbations in Patients With Type 2 Diabetes on Glucagon-like Peptide-1 Receptor Agonists
    Foer, D.
    Strasser, Z. H.
    Cui, J.
    Cahill, K. N.
    Murphy, S. N.
    Karlson, E. W.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [9] Overview of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Patients with Type 2 Diabetes
    Tran, Kelvin Lingjet
    Park, Young In
    Pandya, Shalin
    Muliyil, Navin John
    Jensen, Brandon David
    Huynh, Kovin
    Nguyen, Quang T.
    AMERICAN HEALTH AND DRUG BENEFITS, 2017, 10 (04): : 178 - 187
  • [10] Glucagon-Like Peptide-1 Receptor Agonists for Type 2 Diabetes: A Clinical Update of Safety and Efficacy
    Drab, Scott R.
    CURRENT DIABETES REVIEWS, 2016, 12 (04) : 403 - 413
12345